home > pmps > autumn 2019 > the impact of emerging trends
Pharmaceutical Manufacturing and Packing Sourcer

The Impact of Emerging Trends

Quality assurance is critical in all industries, but in the pharmaceutical supply chain, the cost at stake is higher than most. As the industry shifts towards high-precision, low-volume therapies, pharma shipments become more sensitive, more expensive, and there are significant repercussions for temperature excursions or delayed deliveries. With the global pharma cold chain expected to reach $18 billion in spending by 2022, the impact of errors during transportation can result in compounded inefficiencies and increased costs throughout the entire supply chain, which ultimately affects the patients relying on these treatments.

Today, more rigorous transportation and storage requirements, such as advanced temperature control, sophisticated packaging, and additional monitoring and tracking requirements, are shaping the pharma distribution industry. The supply chain’s complexity is expanding; there is growing local and multi-jurisdictional regulatory oversight and increasing data requirements – all while precise delivery windows are shrinking. These shifting industry dynamics have led to significant changes in the way many pharma products are handled and highlight the industry’s need for high-quality specialty logistics solutions. Specifically, these solutions and their providers must address three critical drivers of change to maintain quality control: increasingly innovative therapies, expanding regulations, and the continued globalisation of the supply chain.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

About the author

Dr Ruediger Lomb is Vice President of Global Quality and Compliance for World Courier, as well as for Integrated Commercialisation Solutions, which are both AmerisourceBergen companies. In his role, Ruediger oversees the quality programme for both entities, ensuring facility and process compliance with all current and future GxP standards such as relevant FDA guidelines, the most recent EU GMP guidelines, and other relevant quality standards. He is a licensed pharmacist and holds a PhD in Pharmaceutical Biochemistry.

Print this page
Send to a friend
Privacy statement
News and Press Releases

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

• 3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use • Beginning of Phase I clinical trial in a group of 10 patients
More info >>

White Papers

Characterisation of Biopharmaceutical Proteins

Reading Scientific Services Ltd (RSSL)

Over the next five years it is anticipated that there is going to be an explosion in the numbers of biosimilar products coming to market as patents expire. Consequently, in line with regulatory guidance, there will be a commensurate need to provide full characterisation of such biopharmaceuticals. The purpose of this article is to describe the array of the more common techniques used in biopharmaceutical characterisation (typically of protein or polypeptide). For full characterisation of a protein, the protein�s primary, secondary and tertiary structure as well as its physiochemical properties should be assessed.
More info >>

Industry Events

World Vaccine Congress Europe

18-21 October 2020, Barcelona, Spain

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement